ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Publications


 
    Poster presented at 2020 Annual Meeting of the Clinical Oncology Society of Australia (COSA), “Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma”.  
 
    Publication in international journal (European Urology Oncology) strengthens case for Veyonda as a safe and possibly life-prolonging treatment in late-stage prostate cancer  
 
    DARRT-1 Interim Data Presented To Conference  
 
    LuPIN Data Being Presented To Conference  
 
    Abstract first published in the Journal of Nuclear Medicine. Interim results of the LuPIN trial. Oral presentation at the Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, June 2019 Anaheim CA.  
 
    A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  

Poster at COSA Annual Meeting Perth November 2018

 
    Trial in Progress: NOX66 in combination with Palliative Radiotherapy in patients with CRPC – a Phase 1 safety and dose finding study  

Poster at COSA Annual Meeting Perth November 2018

 
    NOX66 and Palliative Radiotherapy in Patients with Late-Stage Prostate Cancer- A Phase 1b Proof of Concept and Dose Confirmation Study  

Poster presented at Australian and New Zealand Urogenital and Prostate Cancer (ANZUP) Clinical Trials Group Annual Scientific Meeting, Sydney. July 8-10 2018

 
    A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  

End- of- study clinical data. Poster at the American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago. June 1-5, 2018

 
    NOX66 Plus Low Dose Carboplatin CEP-1 Study Interim Trial Results  

Poster at ESMO 2018 International Congress on Targeted Anticancer Therapies,
Paris.  March 5-7, 2018

 
    NOX66 Plus Carboplatin - Phase 1 Signalling Study  

 Oral Presentation at ESMO Asia 2017 Conference
 Singapore, November 17-19   2017

 
    Idronoxil levels of patients receiving NOX66  

Poster at the Clinical Oncology Society of Australia ( COSA) Annual Scientific Meeting
Sydney, Australia. November 13-15, 2017

 
    ENOX2 levels of patients receiving NOX66  

Poster at the Clinical Oncology Society of Australia ( COSA) Annual Scientific Meeting
Sydney, Australia. November 13-15, 2017

 
    Trial Design: Safety of NOX66 in Combination with Palliative Dose Radiotherapy - A Phase 1 Dose Escalation Study  

Poster at the Clinical Oncology Society of Australia ( COSA) Annual Scientific Meeting
Sydney, Australia. November 13-15, 2017

 
    Chemosensitization of Carboplatin by NOX66  

Poster at the European Society for Medical Oncology 2017 (ESMO) Congress
Madrid, Spain. September 8-12, 2017